Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
Pirozzi F, Poto R, Aran L, Cuomo A, Galdiero MR, Spadaro G, Abete P, Bonaduce D, Marone G, Tocchetti CG, Varricchi G, Mercurio V.
Pirozzi F, et al.
Curr Oncol Rep. 2021 Jan 7;23(2):13. doi: 10.1007/s11912-020-01002-w.
Curr Oncol Rep. 2021.
PMID: 33415405
Free PMC article.
Review.
PURPOSE OF REVIEW: Immune checkpoint inhibitors, such as monoclonal antibodies targeting CTLA-4, PD-1, and PD-L1, have improved the outcome of many malignancies, but serious immune-related cardiovascular adverse events have been observed. Patients' risk factors for these toxiciti …
PURPOSE OF REVIEW: Immune checkpoint inhibitors, such as monoclonal antibodies targeting CTLA-4, PD-1, and PD-L1, have improved the outcome …